vijay84bhu@gmail.com

vijay84bhu@gmail.com's picture
ScienceStream
  • There are no activities to show.

User WAYS points

WAYS Points
0

Member Profile

Academic Level
PI
Position
Laboratory Director
Working Sector
Secondary School / College / University
Highest Degree
Ph. D.
Discipline
Life Sciences: Biochemistry
Reseach Topic
Infectious Diseases
Publications

1. Perry MR, Prajapati VK, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Fairlamb AH, Boelaert M, Picado A. Arsenic Exposure and Outcomes of Antimonial Treatment in Visceral Leishmaniasis Patients in Bihar, India: A Retrospective Cohort Study. PLoS Neglected Tropical Diseases. 2;9(3), 2015, e0003518. (IF- 4.69)

2. Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanershchot M, Dujardin JC, Sundar S; In vitro susceptibility of Leishmania donovani to Miltefosine in Indian Visceral Leishmaniasis. American Journal of Tropical Medicine & Hygiene, 89 (4), 2013, 750-754. (IF-2.59)

3. Prajapati VK* and Mehrotra S. Advances in the Diagnosis of Visceral Leishmaniasis. Journal of Molecular Biomarker and Diagnosis. 4 (2); 2013, 1000e118. (IF- 2.04)

4. Prajapati VK, Mehrotra S, Gautam S, Rai M and Sundar S; In Vitro Antileishmanial Drug Susceptibility of Clinical Isolates from Patients with Indian Visceral Leishmaniasis- Status of Newly Introduced Drugs. American Journal of Tropical Medicine & Hygiene. 87(4), 2012, 655–657. (IF-2.59)

5. Sundar S, Singh A, Rai M, Prajapati VK, Singh A, Ostyn B, Boeleart M, Dujardin JC, Chakravarty J; Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis after a Decade of Use in India. Clinical Infectious Diseases. 2012 Aug; 55 (4): 543-50. (IF- 9.374) (Published as a News in Nature doi:10.1038/nature.2013.12553)

6. Verma RK, Prajapati VK, Verma GK, Chakraborti D, Sundar S, Rai M, Dubey VK, Singh MS; Molecular docking and in vitro antileishmanial evaluation of chromene-2-thione analogues. ACS Medicinal Chemistry Letters. 3 (3), 2012, 243–247. (IF- 3.311)

7. Prajapati VK, Yadav TP, Awasthi K, Rai M, Srivastava ON and Sundar S; An Oral Formulation of Amphotericin B Attached to Functionalized Carbon Nanotubes is an Effective Treatment for Experimental Visceral Leishmaniasis. Journal of Infectious Diseases, 205 (2), 2012: 333-6. (IF- 5.848)

8. Srivastava P, Prajapati VK, Rai M, Sundar M. An unusual case of Amphotericin B refractoriness in Visceral Leishmaniasis from a non-endemic region of India. Journal of Clinical Microbiology; 49 (8) : 2011; 3088-91. (IF- 4.153)

9. Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S; Targeted killing of Leishmania donovani in vivo and in vitro with Amphotericin B attached to functionalized Carbon Nanotubes; Journal of Antimicrobial Chemotherapy, 66 (4): 2011; 874-9. (IF- 5.338) (Published as research highlight by journal Nature; doi:10.1038/nindia.2011.74)

10. Srivastava P, Prajapati VK, Vanaerschot M, Auwera GVD, Dujardin JC, Sundar JC. Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India. Infection, Genetics and Evolution, 10 (7): 2010; 1145-50. (IF- 2.768)

11. Maurya R, Mehrotra S, Prajapati VK, Nylén S, Sacks D, Sundar S. Evaluation of Blood agar micro-titer plates for culturing Leishmania parasites to titrate the parasite burden in spleen and peripheral blood of VL patients. Journal of Clinical Microbiology. 48(5): 2010; 1932-4. (IF- 4.153)

12. Maurya R, Kumar R, Prajapati VK, Manandhar KD, Sacks D, Sundar S, Nylén S. Human visceral leishmaniasis is not associated with expansion or accumulation Foxp3+ CD4 cells in blood or spleen. Parasite Immunology, 32, 2010, 479–483. (IF- 2.208)

13. Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S. Antileishmanial activity of nano-amphotericin B deoxycholate. Journal of Antimicrobial Chemotherapy, 62(2), 2008:376-80. (IF- 5.338)

14. Manandhar KD, Yadav TP, Prajapati VK, Basukala O, Aganja RP, Dude A, Shrivastav ON, Sundar S. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach. Advances in Experimental Medicine and Biology. 808: 2014; 77-91. (IF- 2.012)

15. Hazra S, Ghosh S, Sarma MD S, Sharma S, Das M, Saudagar P, Prajapati VK, Dubey VK, Sundar S, Hazra B; Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of Leishmania donovani. Experimental Parasitology. 135 (2013) 407-413. (IF- 2.154)

16. Bhardwaj A, Arora S, Prajapati VK, Singh S, Singh AP. Cancer Stemness- Regulating Micrornas: Role, Mechanisms and Therapeutic Potential; Current Drug Targets. 14 (10) : 2013; 1175-84. (IF- 3.848)

17. Dayakar A, Chandrasekaran S, Prajapati VK, Veronica TSJR, Sundar S, Maurya R;A rapid method to assess the stage differentiation in Leishmania donovani by flow cytometry. Experimental Parasitology. 132, (2012) 495–500. (IF- 2.154)

18. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK,V. Ramesh, Sundar S, Schonian G, Dujardin JC, Salotra P; Drug Susceptibility in Leishmania Isolates following Miltefosine Treatment in cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis. PLoS Neglected Tropical Diseases. 6 (5), 2012;e1657. (IF- 4.69)

19. Sundar S and Prajapati VK; Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. Current Medicinal Chemistry; 19, 36, 2012; 3196-3202. (IF-4.07)

20. Hazra S, Ghosh S, Debnath S, Seville S, Prajapati VK, Wright CW, Sundar S, Hazra B. Antileishmanial activity of cryptolepine analogues, and apoptotic effects of 2, 7-dibromocryptolepine against Leishmania donovani promastigotes. Parasitology Research. 111, 2012:195–203. (IF- 2.852)

21. Perry M, Wyllie S, Prajapati VK, Feldmann J, Sundar S, Boelaert M, Fairlamb AH. Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian Subcontinent? PLoS Neglected Tropical Disease; 5 (9):201; e1227. (IF- 4.69)

22. Mukhopadhyay R, Mukherjee R, Mukherjee B, Naskar M, Mandal D, Decupere S, Ostyn B, Prajapati VK, Sundar S, Dujardin JC, Roy S. Characterisation of Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. International Journal for Parasitology, 41(13-14):2011; 1311-21. (IF- 3.637)

Prizes / Awards

1. INSA Medal for Young Scientist-2015 in Health Sciences from INSA, New Delhi, India.
2. Elected as MNASc, (Member, The National Academy of Sciences, India) May 2014.
3. Best Speaker Award in Global Infectious Diseases training program 2013 at ICGEB, Cape Town, South Africa.
4. Ranbaxy Science Scholar Award-2011 for young scientist from Ranbaxy Science Foundation, Gurgaon, India.
5. WHO award to attend “Advanced WHO-IRTC/UNIL Course on Immunology, Vaccinology and Biotechnology applied to Leishmania” at University of Lausanne, Switzerland, organized by Prof Fabienne Tacchini-Cottier in October 2011.
6. Certificate of Merit from Nanoscience and Technology Unit, BHU for R&D effort on Nanomedicine drug delivery on the occasion of India Independence day, August 2010.
7. European Commission fellowship for six week internship with Prof. Jean-Claude Dujardin in the Institute of Tropical Medicine, Antwerp, Belgium, and Prof. Louis Maes at University of Antwerp, Belgium, April-May 2009.
8. Editorial board member - BioMed Research International (IF-2.7)
9. Editorial board member- Journal of Molecular Biomarkers & Diagnosis (IF-1.98)
10. Advisor- The Journal of Infection in Developing Countries (IF-1.2)
11. Editorial board member - Journal of Infectious Diseases and Therapy
12. Editorial board member - Future Science OA
13. Editorial board member - SDRP Journal of Infectious Diseases and Microbiology
14. Editorial board member - SDRP Journal of Molecular Medicine
15. Volunteer Reviewer- PLoS ONE, Drug Design Development and Therapy; International Journal of Nanomedicine; Bioorganic & Medicinal Chemistry Letters, Infection and Drug Resistance; OncoTargets and Therapy; International Journal of Nanoparticles, Frontiers in Genetics.

Research Tags
Leishmaniasis, nanomedicine, Drug susceptibility, Amphotericin B, Miletfosine, Leishmania donovani, Jaundice, Molecular Docking, Molecular Dynamics, ADMET, Infectious Diseases
Bio

I born and brought up in small village of Varanasi in a farmer family. I did B.Sc. and M.Sc. from Faculty of Sciences, Banaras Hindu University and then PhD from Institute of Medical Sciences, Banaras Hindu University, India. My research work was based on chemotherapy of visceral leishmaniasis. During PhD for my research contribution, I was awarded young scientist award from Ranbaxy Science Foundation, Gurgaon, India in the year 2011. After PhD, I worked as Scientist in Department of Medicine, Banaras Hindu University for one year (from Dec 2011 to Nov 2012). I was the postdoc fellow in University of South Alabama, United States of America before joining CURAJ. I have been visited several countries such as Belgium, Italy, Germany, Switzerland, Brazil, South Africa and Nepal on the invitation and full support of host institution to present my research work or for collaboration work. I have been awarded by INSA Medal for Young Scientist in the Health Sciences for my research contribution. Till today, I have published 22 research article in international journals with more than 400 citations.

General and Contact Information

Title
Dr.
First Name
Vijay Kumar
Last Name
Prajapati
Date of Birth
05/07/1984
Country of Origin
India
Country of Residence
India
City
Varanasi
Your Website
http://vkprajapati-lab.webs.com/
Languages
Hindi and English

History

Member for
1 year 32 weeks
Blog
View recent blog entries